6.06
+0.02(+0.33%)
Currency In USD
| Previous Close | 6.04 |
| Open | 6.11 |
| Day High | 6.25 |
| Day Low | 5.84 |
| 52-Week High | 7.31 |
| 52-Week Low | 1.31 |
| Volume | 69,285 |
| Average Volume | 167,403 |
| Market Cap | 128.72M |
| PE | -0.56 |
| EPS | -10.85 |
| Moving Average 50 Days | 4.85 |
| Moving Average 200 Days | 2.85 |
| Change | 0.02 |
If you invested $1000 in CAMP4 Therapeutics Corporation (CAMP) since IPO date, it would be worth $565.3 as of January 14, 2026 at a share price of $6.06. Whereas If you bought $1000 worth of CAMP4 Therapeutics Corporation (CAMP) shares 1 year ago, it would be worth $1,620.32 as of January 14, 2026 at a share price of $6.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upre
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
GlobeNewswire Inc.
Dec 18, 2025 12:10 PM GMT
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upre
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
GlobeNewswire Inc.
Dec 18, 2025 12:00 PM GMT
Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4 to receive $17.5 million upfront and eligible for additional milestone-based payments,